Related stories
NNIT A/S - Q3 2026 REVENUE DKK 409.6M, CONSTANT CURRENCY REVENUE GROWTH -5.9%
L impact | EQUITY | Nov 05, 2026, 05:23 PM UTC
REG-NNIT A/S: Performance progressing as planned
NNIT A/S: Performance progressing as planned Q3 2026 key highlights NNIT’s financial performance was
L impact | EQUITY | Nov 05, 2026, 05:22 PM UTC
Cummins Reports Third-Quarter 2026 Revenue of $9.44B, EPS of $8.25
Cummins said third-quarter sales and earnings increased year over year. Higher sales lifted gross margin, while higher compensation expenses partly offset the gains; the company al
M impact | EQUITY | Nov 05, 2026, 05:21 PM UTC
VIRBAC CORPORATION APPOINTS JASON BAILEY AS CFO AND ELIJAH REID AS VP OF HR IN A CONTINUOUS EFFORT TO TRANSFORM THE ORGANIZATION AND ACCELER
VIRBAC CORPORATION APPOINTS JASON BAILEY AS CFO AND ELIJAH REID AS VP OF HR IN A CONTINUOUS EFFORT T
L impact | EQUITY | Nov 05, 2026, 05:21 PM UTC
EZCORP publishes update to financial calendar
EZCORP publishes update to financial calendar EZCORP will release fourth-quarter and full-year f
L impact | EQUITY | Nov 05, 2026, 05:21 PM UTC
ImmunoGenesis Announces Two Publications Highlighting the Potential of IMGS-203, a Novel Stimulator of Interferon Genes (STING) Agonist, to
HOUSTON, Nov. 5, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing inn
L impact | EQUITY | Nov 05, 2026, 05:20 PM UTC